| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 17/11/2024 | 13:30 | PR Newswire (US) | Carisma Therapeutics Presents Promising New Preclinical Data on Engineered Macrophages for the Treatment of Liver Fibrosis at AASLD The Liver Meeting® 2024 | NASDAQ:CARM | Carisma Therapeutics Inc |
| 08/11/2024 | 13:30 | PR Newswire (US) | Carisma Unveils Promising Pre-Clinical Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma | NASDAQ:CARM | Carisma Therapeutics Inc |
| 07/11/2024 | 13:39 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:CARM | Carisma Therapeutics Inc |
| 07/11/2024 | 13:35 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:CARM | Carisma Therapeutics Inc |
| 07/11/2024 | 13:30 | PR Newswire (US) | Carisma Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights | NASDAQ:CARM | Carisma Therapeutics Inc |
| 06/11/2024 | 17:45 | Business Wire | CARMILA: Information Concerning the Total Number of Voting Rights and Share | NASDAQ:CARM | Carisma Therapeutics Inc |
| 06/11/2024 | 17:45 | Business Wire | CARMILA : Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L.233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des marchés financiers | NASDAQ:CARM | Carisma Therapeutics Inc |
| 05/11/2024 | 15:05 | PR Newswire (US) | Carisma Therapeutics to Present New Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma at SITC 2024 | NASDAQ:CARM | Carisma Therapeutics Inc |
| 01/11/2024 | 21:31 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:CARM | Carisma Therapeutics Inc |
| 01/11/2024 | 21:30 | Edgar (US Regulatory) | Form 3 - Initial statement of beneficial ownership of securities | NASDAQ:CARM | Carisma Therapeutics Inc |
| 30/10/2024 | 21:30 | PR Newswire (US) | Carisma Therapeutics Announces Changes to its Board of Directors | NASDAQ:CARM | Carisma Therapeutics Inc |
| 17/10/2024 | 17:45 | Business Wire | Carmila: Third-quarter 2024 Financial Information | NASDAQ:CARM | Carisma Therapeutics Inc |
| 17/10/2024 | 17:45 | Business Wire | Carmila : Information financière au 30 septembre 2024 | NASDAQ:CARM | Carisma Therapeutics Inc |
| 16/10/2024 | 15:54 | Business Wire | CARMILA : COMMUNIQUÉ DE PRESSE EN DATE DU 16 OCTOBRE 2024 | NASDAQ:CARM | Carisma Therapeutics Inc |
| 04/10/2024 | 15:05 | PR Newswire (US) | Carisma Therapeutics Announces Upcoming Presentations at SITC 2024 | NASDAQ:CARM | Carisma Therapeutics Inc |
| 02/10/2024 | 17:45 | Business Wire | Carmila : Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L.233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des marchés financiers | NASDAQ:CARM | Carisma Therapeutics Inc |
| 02/10/2024 | 17:45 | Business Wire | Carmila: Information Concerning the Total Number of Voting Rights and Share | NASDAQ:CARM | Carisma Therapeutics Inc |
| 25/09/2024 | 12:25 | Business Wire | CARMILA : COMMUNIQUÉ DE PRESSE EN DATE DU 25 SEPTEMBRE 2024 | NASDAQ:CARM | Carisma Therapeutics Inc |
| 24/09/2024 | 18:26 | Business Wire | CARMILA : COMMUNIQUÉ DE PRESSE EN DATE DU 24 SEPTEMBRE 2024 | NASDAQ:CARM | Carisma Therapeutics Inc |
| 24/09/2024 | 18:10 | Business Wire | SUCCES DE L'OFFRE DE RACHAT SUR LES OBLIGATIONS CARMILA AVEC UN MONTANT TOTAL RACHETE DE 200.100.000 D'EUROS D'OBLIGATIONS | NASDAQ:CARM | Carisma Therapeutics Inc |
| 24/09/2024 | 18:10 | Business Wire | Successful Completion of Tender Offer on Carmila’s Bonds With €200,100,000 of Bonds Tendered | NASDAQ:CARM | Carisma Therapeutics Inc |
| 17/09/2024 | 18:30 | Business Wire | Carmila Successfully Issues Inaugural €300M 7-Year Green Bond, Paying a Fixed Annual Coupon of 3.875% | NASDAQ:CARM | Carisma Therapeutics Inc |
| 17/09/2024 | 18:30 | Business Wire | SUCCES DE L’EMISSION INAUGURALE D’UN « GREEN BOND » DE 300 M€ ET DE MATURITE 7 ANS, AVEC UN COUPON FIXE ANNUEL DE 3,875% | NASDAQ:CARM | Carisma Therapeutics Inc |
| 16/09/2024 | 10:47 | Business Wire | Carmila Announces the Launch of a Tender Offer on Its Existing Notes Maturing in May 2027, March 2028, October 2028 and April 2029, and Announces Its Intention to Issue New Notes | NASDAQ:CARM | Carisma Therapeutics Inc |
| 16/09/2024 | 10:47 | Business Wire | CARMILA ANNONCE LE LANCEMENT D'UNE OFFRE DE RACHAT SUR SES OBLIGATIONS EXISTANTES VENANT À ÉCHÉANCE EN MAI 2027, MARS 2028, OCTOBRE 2028 ET AVRIL 2029, ET ANNONCE SON INTENTION D'ÉMETTRE DE NOUVELLES OBLIGATIONS | NASDAQ:CARM | Carisma Therapeutics Inc |
| 10/09/2024 | 13:30 | PR Newswire (US) | Carisma and Moderna Expand Collaboration to Develop Two In Vivo CAR-M Therapies for Autoimmune Diseases | NASDAQ:CARM | Carisma Therapeutics Inc |
| 09/09/2024 | 17:45 | Business Wire | Carmila: Information Concerning the Total Number of Voting Rights and Share, Provided Pursuant to Article L.233-8 II of the Code de commerce (French Commercial Code) and Article 223-16 of the Règlement général de l’Autorité des marchés financiers | NASDAQ:CARM | Carisma Therapeutics Inc |
| 06/09/2024 | 16:07 | Business Wire | CARMILA : COMMUNIQUÉ DE PRESSE DU 6 SEPTEMBRE 2024 | NASDAQ:CARM | Carisma Therapeutics Inc |
| 03/09/2024 | 13:30 | PR Newswire (US) | Carisma Therapeutics to Present at Upcoming Conferences | NASDAQ:CARM | Carisma Therapeutics Inc |
| 08/08/2024 | 13:30 | PR Newswire (US) | Carisma Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights | NASDAQ:CARM | Carisma Therapeutics Inc |